Cargando…
Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
BACKGROUND: Immune checkpoint inhibitors (ICIs) were approved to have a significant antitumor activity in various tumor types. In practice, some patients do not seem to benefit from ICIs but rather to have accelerating disease. The aim of this study was to evaluate hyperprogression in patients with...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637510/ https://www.ncbi.nlm.nih.gov/pubmed/31315610 http://dx.doi.org/10.1186/s12885-019-5921-9 |